心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2020 ACC专家共识：口服抗凝药患者出血管理的决策路径

2020-07-10 美国心脏病学会 J Am Coll Cardiol . 2020 Jul 10;S0735-1097(20)35154-8.

口服抗凝药抗凝药

2020年7月，美国心脏病学会(ACC)更新发布了口服抗凝药患者出血管理的决策路径共识，本文是对2017年版共识的更新。本文重点为使用直接口服抗凝药物（DOAC）和维生素K拮抗剂（VKA）治疗出血患者

中文标题：

2020 ACC专家共识：口服抗凝药患者出血管理的决策路径

英文标题：

2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants

发布机构：

美国心脏病学会

发布日期：

2020-07-10

简要介绍：

2020年7月，美国心脏病学会(ACC)更新发布了口服抗凝药患者出血管理的决策路径共识，本文是对2017年版共识的更新。本文重点为使用直接口服抗凝药物（DOAC）和维生素K拮抗剂（VKA）治疗出血患者的管理。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 ACC专家共识：口服抗凝药患者出血管理的决策路径.pdf)] GetToolGuiderByIdResponse(projectId=1, id=bba1c1c0019a09c7, title=2020 ACC专家共识：口服抗凝药患者出血管理的决策路径, enTitle=2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants, guiderFrom=J Am Coll Cardiol . 2020 Jul 10;S0735-1097(20)35154-8., authorId=0, author=, summary=2020年7月，美国心脏病学会(ACC)更新发布了口服抗凝药患者出血管理的决策路径共识，本文是对2017年版共识的更新。本文重点为使用直接口服抗凝药物（DOAC）和维生素K拮抗剂（VKA）治疗出血患者, cover=https://img.medsci.cn/2020727/1595780407692_2020535.jpg, journalId=0, articlesId=null, associationId=849, associationName=美国心脏病学会, associationIntro=null, copyright=0, guiderPublishedTime=Fri Jul 10 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年7月，美国心脏病学会(ACC)更新发布了口服抗凝药患者出血管理的决策路径共识，本文是对2017年版共识的更新。本文重点为使用直接口服抗凝药物（DOAC）和维生素K拮抗剂（VKA）治疗出血患者的管理。</p> </div> </div> </div>, tagList=[TagDto(tagId=3159, tagName=口服抗凝药), TagDto(tagId=4588, tagName=抗凝药)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=4588, guiderKeyword=抗凝药, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5900, appHits=634, showAppHits=0, pcHits=1968, showPcHits=5266, likes=4, shares=38, comments=31, approvalStatus=1, publishedTime=Mon Jul 27 00:21:40 CST 2020, publishedTimeString=2020-07-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Jul 27 00:20:19 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 19:29:00 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 ACC专家共识：口服抗凝药患者出血管理的决策路径.pdf)])
2020 ACC专家共识：口服抗凝药患者出血管理的决策路径.pdf
下载请点击：
评论区 (25)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2241805, encodeId=ee85224180525, content=大有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f40b9566918, createdName=ms7000001939434768, createdTime=Wed Dec 11 11:16:02 CST 2024, time=2024-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241804, encodeId=55a32241804c3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f40b9566918, createdName=ms7000001939434768, createdTime=Wed Dec 11 11:15:38 CST 2024, time=2024-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190266, encodeId=ffa011902666a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210701/06e9c0d78bfd4893b14902966e1261ec/f1b6a740567e43c1ac62ff3560f2d436.jpg, createdBy=2f8b1998595, createdName=猫咪猪旺旺, createdTime=Sat Feb 05 11:57:06 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081561, encodeId=e3ac108156142, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/2POAEAIDY0kOC5iadvH0N1phKLpWSnTEOydItqibAysHD7WtBFicibGDDlwjvkQ3c3oIwQZzngI0ZGqgHgiadz3HOgA/132, createdBy=e3362531135, createdName=ff224, createdTime=Sat Dec 18 16:23:15 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005057, encodeId=cd20100505ea0, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Wed Aug 04 09:41:12 CST 2021, time=2021-08-04, status=1, ipAttribution=)]
    2024-12-11 ms7000001939434768

    大有收获

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2241805, encodeId=ee85224180525, content=大有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f40b9566918, createdName=ms7000001939434768, createdTime=Wed Dec 11 11:16:02 CST 2024, time=2024-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241804, encodeId=55a32241804c3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f40b9566918, createdName=ms7000001939434768, createdTime=Wed Dec 11 11:15:38 CST 2024, time=2024-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190266, encodeId=ffa011902666a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210701/06e9c0d78bfd4893b14902966e1261ec/f1b6a740567e43c1ac62ff3560f2d436.jpg, createdBy=2f8b1998595, createdName=猫咪猪旺旺, createdTime=Sat Feb 05 11:57:06 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081561, encodeId=e3ac108156142, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/2POAEAIDY0kOC5iadvH0N1phKLpWSnTEOydItqibAysHD7WtBFicibGDDlwjvkQ3c3oIwQZzngI0ZGqgHgiadz3HOgA/132, createdBy=e3362531135, createdName=ff224, createdTime=Sat Dec 18 16:23:15 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005057, encodeId=cd20100505ea0, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Wed Aug 04 09:41:12 CST 2021, time=2021-08-04, status=1, ipAttribution=)]
    2024-12-11 ms7000001939434768

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2241805, encodeId=ee85224180525, content=大有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f40b9566918, createdName=ms7000001939434768, createdTime=Wed Dec 11 11:16:02 CST 2024, time=2024-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241804, encodeId=55a32241804c3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f40b9566918, createdName=ms7000001939434768, createdTime=Wed Dec 11 11:15:38 CST 2024, time=2024-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190266, encodeId=ffa011902666a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210701/06e9c0d78bfd4893b14902966e1261ec/f1b6a740567e43c1ac62ff3560f2d436.jpg, createdBy=2f8b1998595, createdName=猫咪猪旺旺, createdTime=Sat Feb 05 11:57:06 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081561, encodeId=e3ac108156142, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/2POAEAIDY0kOC5iadvH0N1phKLpWSnTEOydItqibAysHD7WtBFicibGDDlwjvkQ3c3oIwQZzngI0ZGqgHgiadz3HOgA/132, createdBy=e3362531135, createdName=ff224, createdTime=Sat Dec 18 16:23:15 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005057, encodeId=cd20100505ea0, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Wed Aug 04 09:41:12 CST 2021, time=2021-08-04, status=1, ipAttribution=)]
    2022-02-05 猫咪猪旺旺

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2241805, encodeId=ee85224180525, content=大有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f40b9566918, createdName=ms7000001939434768, createdTime=Wed Dec 11 11:16:02 CST 2024, time=2024-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241804, encodeId=55a32241804c3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f40b9566918, createdName=ms7000001939434768, createdTime=Wed Dec 11 11:15:38 CST 2024, time=2024-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190266, encodeId=ffa011902666a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210701/06e9c0d78bfd4893b14902966e1261ec/f1b6a740567e43c1ac62ff3560f2d436.jpg, createdBy=2f8b1998595, createdName=猫咪猪旺旺, createdTime=Sat Feb 05 11:57:06 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081561, encodeId=e3ac108156142, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/2POAEAIDY0kOC5iadvH0N1phKLpWSnTEOydItqibAysHD7WtBFicibGDDlwjvkQ3c3oIwQZzngI0ZGqgHgiadz3HOgA/132, createdBy=e3362531135, createdName=ff224, createdTime=Sat Dec 18 16:23:15 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005057, encodeId=cd20100505ea0, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Wed Aug 04 09:41:12 CST 2021, time=2021-08-04, status=1, ipAttribution=)]
    2021-12-18 ff224

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2241805, encodeId=ee85224180525, content=大有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f40b9566918, createdName=ms7000001939434768, createdTime=Wed Dec 11 11:16:02 CST 2024, time=2024-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241804, encodeId=55a32241804c3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f40b9566918, createdName=ms7000001939434768, createdTime=Wed Dec 11 11:15:38 CST 2024, time=2024-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190266, encodeId=ffa011902666a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210701/06e9c0d78bfd4893b14902966e1261ec/f1b6a740567e43c1ac62ff3560f2d436.jpg, createdBy=2f8b1998595, createdName=猫咪猪旺旺, createdTime=Sat Feb 05 11:57:06 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081561, encodeId=e3ac108156142, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/2POAEAIDY0kOC5iadvH0N1phKLpWSnTEOydItqibAysHD7WtBFicibGDDlwjvkQ3c3oIwQZzngI0ZGqgHgiadz3HOgA/132, createdBy=e3362531135, createdName=ff224, createdTime=Sat Dec 18 16:23:15 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005057, encodeId=cd20100505ea0, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Wed Aug 04 09:41:12 CST 2021, time=2021-08-04, status=1, ipAttribution=)]
    2021-08-04 gqylhd

    赞

    0

以上为热门评论，梅斯医学App还有更多内容